Scene 1

Development of a combined novel live attenuated vaccine against malaria and leishmaniasis

Participant Name 1: Dr. Swati Garg 					Team No: 18 Participant Name 2: Mr. Shubham Rajput  Participant Name 3: Ms.  Aashima  Gupta

Audio Recording 17-Jul-2021 at 11:31:13 PM

Scene 2

Difficult to culture. Mutation of parasites Antigenic variation Lack of suitable animal model Lack of effective adjuvants Development of adequate immune response

Combinantion  vaccine against malaria and kala-azar not available.  No vaccine available that provides full protection against individual disease.

Audio Recording 17-Jul-2021 at 11:33:44 PM

Scene 3

Estimated deaths
from malaria, 000
900
750
600
450
300
150
2000 02
04
Source: WHO
06
08
10
12
Spending on
malaria, $bn
3.0
2.5
2.0
1.5
1.0
0.5
15*
*Forecast

https:// oxfamblogs.org /fp2p/links-i-liked-66/

219 million reported cases of the disease in 2017 435,000 deaths due to malaria in 2017 92% of malaria cases and 93% of associated deaths

Leishmaniasis, specifically kala-azar, is difficult to eliminate. India is highly affected by the disease.

Audio Recording 17-Jul-2021 at 11:34:40 PM

Scene 4

An effective Malaria and leishmaniasis vaccine is much needed requirement of tropical countries. Vaccine will prevent the incidence of both malaria and leishmaniasis in tropical parts of world. This vaccine will be a boon for the people of endemic countries. India, Africa, south-east Asia are the major beneficiary of this vaccine. The combination vaccine will help in the elimination of both the diseases.

Audio Recording 17-Jul-2021 at 11:40:07 PM

Scene 5

Vaccines for visceral leishmaniasis: A review - ScienceDirect

A number of vaccines are under pipeline for malaria and leishmaniasis but none of them provide immunity to both

Audio Recording 17-Jul-2021 at 11:41:22 PM

Scene 6

The vaccine will provide protection to both malaria and leishmaniasis. This will give both B cell and T cell response which is required for development of effective vaccine. The customer has to bear the cost of only vaccine. The vaccine will be safe and can be produced in GLP laboratories.

Lle N e
Leishmania cells
m (C-P-LEXSY)
O
O
Respeese

Detailed working hypothesis for the proposed vaccine

Audio Recording 17-Jul-2021 at 11:42:25 PM

Development of a combined novel live attenuated vaccine against malaria and leishmaniasis

Page 1 (0s)

Page 2 (29s)

Page 3 (1m 10s)

Page 4 (1m 39s)

Page 5 (2m 9s)

Page 6 (2m 39s)